Doseology Sciences Inc. Logo (CNW Group/Doseology Sciences Inc.)
  • Doseology Sciences (MOOD) is expanding the retail reach of its functional mushroom supplements
  • The British Columbia life sciences company’s supplements will soon be available at all 14 top-tier Whole Foods Market Canada locations
  • The company currently has three SKUs in the market, SLEEP, WAKE, and ELEVATE functional mushroom tinctures
  • The products are already available at four Whole Foods locations in British Columbia
  • Doseology Sciences is down 20 percent, trading at $0.04 at 11:45 am ET

Doseology Sciences (MOOD) is expanding the retail reach of its functional mushroom supplements.

The British Columbia life sciences company’s supplements will soon be available at all 14 top-tier Whole Foods Market Canada locations.

The company currently has three SKUs in the market, SLEEP, WAKE, and ELEVATE functional mushroom tinctures. The products are already available at four Whole Foods locations in British Columbia.

The line is made with 100-percent fruiting body mushrooms and adaptogenic plants and is designed for wellness seekers interested in daily support for cognition, mood, immunity and relaxation.

“Whole Foods has a reputation as an industry leader with the highest standards, which makes them an ideal retail partner for our products. This placement will help us generate brand awareness and increase sales while delivering health and wellness results for customers,” said Doseology CEO Ralph Olson.

The company is continuing to build a progressive brand focused on mental health and wellness through cultivation, extraction and innovative nutraceutical and pharmaceutical products. 

Doseology Sciences is down 20 percent, trading at $0.04 at 11:45 am ET.


More From The Market Online

Tilray’s Breckenridge Brewery honours Denver Nuggets with new ale

Tilray Brands (TSX:TLRY) subsidiary Breckenridge Brewery launches a new ale to recognize the 2023 NBA championship-winning Denver Nuggets.

GameStop stock struggles on weak Q4 2023 performance

GameStop Corp. (NYSE:GME) stock struggles after reporting weak Q4 2023 financial results, but it eventually claws back some gains.